A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

PHASE3RecruitingINTERVENTIONAL

Enrollment

570

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

January 28, 2026

Study Completion Date

January 1, 2027

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 until disease progression or for a maximum of 16 cycles

BIOLOGICAL

placebo

Subjects will receive placebo until disease progression or for a maximum of 16 cycles

Trial Locations (1)

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai